Expert Insights on Overcoming Patient Education Gaps, Biosimilar Financial Hurdles

June 29, 2025

Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, explain that widespread biosimilar adoption requires addressing patient and provider education gaps through pharmacists and rectifying perverse financial incentives within health care contract structures.

The Top 5 Biosimilar Articles for the Week of June 23

June 27, 2025

Eye on Pharma: CHMP Aflibercept Decision; Omalizumab Results; Dupilumab Biosimilar Deal

June 26, 2025

Increasing Biosimilar Use Reflects Changing Practice in Pediatric IBD Care

June 25, 2025

Omalizumab Biosimilar Matches Reference Product in Chronic Spontaneous Urticaria

June 24, 2025

Strategies for Effective Biosimilar Education, Adoption

August 25th 2024

By Cameron Santoro

Video

Ivo Abraham, PhD, RN, University of Arizona Cancer Center, suggests implementing targeted educational strategies to overcome physician hesitancy towards biosimilar adoption.

Targeted Incentives Prove Effective in Boosting Adalimumab Biosimilar Uptake in France

August 24th 2024

By Deana Ferreri, PhD

Article

A study comparing 2 different financial incentive programs in France to encourage adalimumab biosimilar use concluded that incentivizing individual clinical units was more effective than incentivizing entire hospitals.

The Top 5 Biosimilar Articles for the Week of August 19

August 23rd 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of August 19, 2024.

Pure-Play Biosimilar Company Reports 10-Fold Revenue Increase for First Half of 2024

August 22nd 2024

By Skylar Jeremias

Article

Alvotech reported $236 million in revenue for the first 6 months of 2024, a 10-fold increase from the same period the year prior. The new figures come after the company received its first 2 FDA approvals in 2024.

Eye on Pharma: Celltrion, Costco Partnership; Amgen Sues Samsung Bioepis; Denosumab Results

August 21st 2024

By Skylar Jeremias

Article

Celltrion's adalimumab-aaty biosimilar is now accessible for all Costco members, while Amgen sues Samsung Bioepis over the latter’s denosumab biosimilar candidate, and GlycoNex progresses its denosumab biosimilar SPD8 to phase 3 trials.

Biosimilar CT-P42 Demonstrates Equivalence to Aflibercept for DME

August 20th 2024

By Cameron Santoro

Article

Biosimilar CT-P42 demonstrated comparable efficacy, safety, and tolerability to reference aflibercept in treating diabetic macular edema (DME).

CMS Announces New Drug Prices Under the IRA, Including for Stelara and Enbrel

August 19th 2024

By Skylar Jeremias

Article

CMS announced negotiated prices for 10 drugs under the Inflation Reduction Act (IRA), sparking mixed reactions, with concerns that including drugs facing imminent biosimilar competition could hinder market access to lower-cost alternatives.

Patent Dance Insights: A Q&A on Reducing Legal Battles in the Biosimilar Landscape

August 18th 2024

By Cameron Santoro

Article

In an interview, Ha Kung Wong, an intellectual property attorney, explained that the Biologics Price Competition and Innovation Act of 2009 provides a structured but optional "patent dance" for biosimilars, which helps streamline patent disputes, potentially reducing litigation and encouraging early settlements.

The Top 5 Biosimilar Articles for the Week of August 12

August 16th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of August 12, 2024.

No Differences in Long-Term Drug Survival Between Biosimilar, Originator TNF Inhibitors

August 15th 2024

By Skylar Jeremias

Article

An analysis of subcutaneous biosimilar and originator tumor necrosis factor (TNF) inhibitors for rheumatic diseases found no significant differences in survival or discontinuation rates due to inefficacy or adverse events, with biosimilars showing lower overall discontinuation rates and higher retention rates.